NADPH oxidase is a major source of reactive oxygen species (ROS) production in the kidney and contributes to renal damage in diabetes. We aimed to examine the role of the NADPH oxidase Nox1 and Nox4 in diabetic nephropathy (DN) using genetic deletion and pharmacological inhibition approaches Venetoclax supplier in streptozotocin induced diabetic mice. Methods: Nox1−/yApoE−/− or Nox4−/−ApoE−/− and their respective wild type or ApoE−/− mice were rendered diabetic via streptozotocin injection. ApoE−/− non-diabetic and diabetic mice were treated with the specific Nox1/4 inhibitor (GKT137831). Animals were culled after 20 weeks and

kidneys were removed for assessment of structural damage, oxidative stress markers, as well as protein expressions extracellular matrix (ECM), pro-fibrotic and pro-inflammatory markers. In vitro, Nox4 was silenced in human podocytes and exposed to high glucose for gene expression analysis and ROS measurements. Results: Deletion of Nox4, but not of Nox1 resulted

in renal protection from glomerular injury as evidenced by attenuated albuminuria, preserved renal structure, reduced glomerular accumulation of ECM proteins as well as attenuated PI3K inhibitor glomerular macrophage infiltration. Administration of GKT137831 to diabetic ApoE−/− mice conferred a similar degree of renoprotection as did deletion of Nox4. In human podocytes, silencing of the Nox4 gene resulted in reduced ROS production and down-regulation of profibrotic markers that are implicated in diabetic

nephropathy. Conclusion: Collectively, Farnesyltransferase these results identify Nox4 is a key source of ROS responsible for kidney injury in diabetes and provide proof of principle for an innovative small molecule approach to treat and/or prevent DN. UJIKE HARUYO1, MAESHIMA YOHEI2, HINAMOTO NORIKAZU1, WATATANI HIROYUKI1, TANABE KATSUYUKI1, MASUDA KANA1, SUGIYAMA HITOSHI1, SATO YASUFUMI3, MAKINO HIROFUMI1 1Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan; 2Dept. of Chronic Kidney Disease and Cardiovascular Disease, Okayama Univ., Okayama, Japan; 3Dept. of Vascular Biology, Institute of Development, Aging, and Cancer, Tohoku Univ., Sendai, Japan Introduction: Diabetic nephropathy is the most common cause of end-stage renal disease, and albuminuria is a risk factor for progressive loss of renal function. Vasohibin-2 (VASH-2) belongs to the Vasohibin family and serves as a pro-angiogenic factor. We previously reported the protective role of exogenous Vasohibin-1, a homologous to VASH-2 and a negative feedback regulator of angiogenesis, in mouse models of diabetic nephropathy. To date, the biological role of VASH-2 in renal disorders is not clarified. In the present study, we aimed to evaluate the potential role of endogenous VASH-2 on the progression of diabetic nephropathy.